Inhibition of SYK activity by SYK-specific inhibitors such as PRT060318 and fostamatinib disodium [37, 38] provides great clinical outcome to certain cancer patients with abnormal SYK activities, indicating that subtype I patients may be benefited from SYK-specific kinase inhibitors. The gene discussed is SYK; the disease is cancer.